Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 41: 1489-1494, 1995;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Demers, L. M.
Right arrow Articles by Lipton, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demers, L. M.
Right arrow Articles by Lipton, A.

Clinical Chemistry, Vol 41, 1489-1494, Copyright © 1995 by American Association for Clinical Chemistry

Biochemical markers of bone turnover in patients with metastatic bone disease

LM Demers, L Costa, VM Chinchilli, L Gaydos, E Curley and A Lipton
Department of Pathology, M.S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey 17033, USA.

Several biochemical markers of bone formation and bone resorption have recently been developed. These markers have been evaluated for clinical utility in patients with metabolic bone disease, including Paget disease and osteoporosis, and for their potential use in cancer patients whose disease has metastasized to bone. We have evaluated seven markers of bone turnover in the plasma and urine of 94 patients with newly diagnosed or progressive malignancy with and without clinical evidence of bone metastases. As determined by a positive bone scan and (or) bone survey, 30 patients had metastases to bone; 51 patients had metastatic cancer without overt bony involvement; and 13 patients had local disease without bone metastases. To evaluate the predictive value of these markers in the metastatic population, we utilized a "Z-score" and logistic regression analysis to distinguish patients with documented bone metastatic disease from those patients without clinical evidence of bone metastases. The higher the Z-score, the better the marker predicts the presence of bone metastases. With this statistical approach, urine N-telopeptide measurements had the highest Z-score and the most significant association with the probability of bone metastases. Urine deoxypyridinoline was the second most predictive marker of bone metastases. Thus, biochemical markers of bone resorption might be of use to predict the presence of bone metastases in cancer patients and to monitor the efficacy of antiresorptive therapy in patients treated for metastatic bone disease.


The following articles in journals at HighWire Press have cited this article:


Home page
 The OncologistHome page
A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman
Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity
Oncologist, September 1, 2007; 12(9): 1035 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Brown, R. J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, and R. E. Coleman
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
J Natl Cancer Inst, January 5, 2005; 97(1): 59 - 69.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. M. Ali, L. M. Demers, K. Leitzel, H. A. Harvey, D. Clemens, N. Mallinak, L. Engle, V. Chinchilli, L. Costa, C. Brady, et al.
Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis
Ann. Onc., March 1, 2004; 15(3): 455 - 459.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M.-H. Le Du and J. L. Millan
Structural Evidence of Functional Divergence in Human Alkaline Phosphatases
J. Biol. Chem., December 13, 2002; 277(51): 49808 - 49814.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Costa, L. M. Demers, A. Gouveia-Oliveira, J. Schaller, E. B. Costa, M. C. de Moura, and A. Lipton
Prospective Evaluation of the Peptide-Bound Collagen Type I Cross-Links N-Telopeptide and C-Telopeptide in Predicting Bone Metastases Status
J. Clin. Oncol., February 1, 2002; 20(3): 850 - 856.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. M. Demers
Biochemical Markers in the Management of Patients with Metastatic Bone Disease
Clin. Chem., August 1, 1999; 45(8): 1131 - 1132.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Berruti, L. Dogliotti, G. Gorzegno, M. Torta, M. Tampellini, M. Tucci, S. Cerutti, M. Mosca Frezet, M. Stivanello, G. Sacchetto, et al.
Differential Patterns of Bone Turnover in Relation to Bone Pain and Disease Extent in Bone in Cancer Patients with Skeletal Metastases
Clin. Chem., August 1, 1999; 45(8): 1240 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
T. G. Rosano, R. T. Peaston, H. G. Bone, H. W. Woitge, R. M. Francis, and M. J. Seibel
Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation
Clin. Chem., October 1, 1998; 44(10): 2126 - 2132.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Magnusson, L. Larsson, G. Englund, B. Larsson, P. Strang, and L. Selin-Sjogren
Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain
Clin. Chem., August 1, 1998; 44(8): 1621 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. D. Clemens, M. V. Herrick, F. R. Singer, and D. R. Eyre
Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption
Clin. Chem., November 1, 1997; 43(11): 2058 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. Withold, F. P. Armbruster, M. Karmatschek, and H. Reinauer
Bone sialoprotein in serum of patients with malignant bone diseases
Clin. Chem., January 1, 1997; 43(1): 85 - 91.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Association for Clinical Chemistry.